Navigation Links
Helix BioPharma Corp. Announces Fiscal 2008 Results
Date:10/28/2008

sents an increase of $188,000 or 6.8% when compared to product revenue in fiscal 2007 of $2,764,000. Product sales of Klean-Prep(TM) continued to grow in fiscal 2008 and more than offset lower sales of Orthovisc(R) in Canada.

License fees and royalties in fiscal 2008 totaled $639,000 and represent an increase of $127,000 or 24.8% when compared to fiscal 2007. The increase is mainly the result of a milestone payment from the sub-licensing arrangement of the Company's biochip technology to Lumera Corporation. Lumera has now given notice of its termination of the sub-license effective December 19, 2008.

Research and development contract revenue in fiscal 2008 totaled $nil and represents a decrease of $148,000 when compared to fiscal 2007. The Company completed a research and development contract in the third quarter of fiscal 2007 and currently has no plans to contract its research and development services out to third parties, but instead is focusing its resources on the development of two product candidates: L-DOS47 and Topical Interferon Alpha-2b.

Cost of sales in fiscal 2008 and 2007 totaled $1,239,000 and $1,139,000, respectively. As a percentage of product revenues, cost of sales in fiscal 2008 and 2007 were 42.0%, 41.2%, respectively. The Canadian dollar's strength over the last three fiscal years has moderated in fiscal 2008 and was range bound, reflecting slight higher cost of sales.

Research and development expenditures in fiscal 2008 totaled $5,064,000 and represent an increase of $948,000 or 23.0% when compared to fiscal 2007. Both Topical Interferon Alpha-2b and DOS47 reflect an increase of 20.6% and 25.0%, respectively. The increase in DOS47 research and development expenditures reflect advancing preclinical costs in preparation for L-DOS47 pre-IND meetings and a Phase I IND filing to occur sometime before the end of Helix's fiscal fourth quarter ending July 31, 2009. The increase in research and development expenditures relate
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma Closes $11.4 Million Private Placement
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
4. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
5. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
6. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
7. Helix BioPharma reports Q2 2008 highlights, financial results
8. Helix BioPharma shareholders vote in favour of management
9. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Helix BioPharma announces Q1 2008 financial results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... Chemical Abstracts Service (CAS), the global...a,s patent office is now the world,s leading produ... China trailed Japan,s patent office, the World In...nited States Patent and Trademark Office (USPTO) f...5, WIPO in 2006, and exceeded Japan for the first ...
(Date:11/23/2009)...ov. 23, 2009 In a provocative new study, a Univer...ioxide emissions the major cause of global warmin... collapses or society builds the equivalent of one...unlikely that there will be any substantial near-t...in carbon dioxide emission rates," says the new pa...
(Date:11/23/2009)...promises ultra-fast communication, computation and...on. But trying to use quantum states as carriers o...ow two physicists have shown, mathematically, how ...unication, while keeping the information intact. T...sical Review Letters and highlighted with a Viewp...
(Date:11/23/2009)...GE,Nev.,Nov.23/PRNewswire-FirstCall/--PDLBioPharma...asestablishedNovember27,2009astheex-dividenddatefo...ingfromthesecuritizationtransactioncompletedonNove...oallstockholdersofrecordontherecorddate,December1,...dividendat$1.67pershareofcommonstockforpurposesoft...
Breaking Biology Technology:China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2
...d CLAREMONT, Calif., June 25 /Xinhua-PRNewswire-Fi...on (OTC Bulletin Board: KWBT),announced that on Ju...Co.,Ltd. (Kiwa Shandong) received approval documen...epublic of China, ratifying Kiwa Shandong to,whole...ng chemical,fertilizers, complex fertilizers and c...
...KET, N.Y., June 25 Lixte,Biotechnology Holdings (...,National Institute of Neurological Disorders and ...) and Lixte Biotechnology Holdings, Inc. extended,...nt (CRADA) to develop,drugs for the treatment of b...as extended through September 2009., Dr. John S. ...
... Mich., June 25 MichBio announced that,Johnson & ...he keynote,speaker for its statewide Expo and Conf... the association for Michigan,s life science indus...e science event attracting,more than 450 attendees...of the most respected professionals in the industr...
Other Biology Technology:Kiwa Bio-Tech Receives Authorization From the Ministry of Commerce of the People's Republic of China to Wholesale Other Fertilizer Manufacturers Products 2Kiwa Bio-Tech Receives Authorization From the Ministry of Commerce of the People's Republic of China to Wholesale Other Fertilizer Manufacturers Products 3Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs 2Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs 3Christine Poon Will Keynote MichBio Expo 2Christine Poon Will Keynote MichBio Expo 3
(Date:11/25/2009)... Death Research Laboratory in the University of Ha...prestigious Johnson & Johnson Focused Funding gran...ll damage in Parkinson,s disease. The award, which...innovation and excellence in science, was announce...onth at an event at the Hyatt Regency Hotel in New...
(Date:11/25/2009)...rofessors recently received funding from the Natio...beneficial to understanding the environment. The t...ood, assistant professor in the Department of Biol... separate research projects. , His first project... and Functions from the Leaf to the Landscape," wi...
(Date:11/24/2009)...day named 12 new grant recipients for 2009. The aw...work across a broad spectrum of lupus research. Al... potential to drive scientific discovery to ultima...of systemic lupus. , The 2009 grants go to both ...ation and include interdisciplinary and highly pro...
Breaking Biology News(10 mins):Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Kent State University professors focus research on the environment with grants totaling $890,000 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Advocate Christ Medical Center Redesignated A 26apos 3BMagnet 26apos 3B Hospital the Highest Nursing Honor 57449 1Advocate Christ Medical Center Redesignated A 26apos 3BMagnet 26apos 3B Hospital the Highest Nursing Honor 57449 2Advocate Christ Medical Center Redesignated A 26apos 3BMagnet 26apos 3B Hospital the Highest Nursing Honor 57449 3Save a Life 3A Join the Kiel Mortgage Marrow thon on September 23 57447 1Save a Life 3A Join the Kiel Mortgage Marrow thon on September 23 57447 2InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture 57446 1InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture 57446 2
...ct. 25, 2007 -- The genes that make a fruit fly,s ...iconius butterfly found in South and Central Ameri... , Bob Reed, assistant professor of ecology and e...d in making insect eye pigments evolved over time ...nding sheds light on the genetic causes of wing pa...
...ah biologists genetically manipulated nematode wor...ame sex part of a study that shows sexual orienta...ok like girls, but act and think like boys, says J...thor of the new study. The [same-sex attraction] b...dy was published online Thursday, Oct. 25 in Curre...
...ale School of Medicine researchers have received $...wn chromosomes and DNA after damage caused by radi...e National Institutes of Health (NIH) is the next ... the lead researcher, Peter Glazer, M.D., chair of...ogy research program at Yale Cancer Center. , W...
Other Biology News:Scientists alter sexual orientation in worms 2Scientists alter sexual orientation in worms 3Scientists alter sexual orientation in worms 4Yale receives $8.4 million to study DNA repair in cancer cells 2
... Alkaline Phosphatase Conjugation Horseradish P...cein Isothiocyanate Conjugation R. Phycoerythrin ...n Conjugation Alexa Fluor 488 Conjugation Alexa ... Rpe-Alexa Fluor 750 Conjugation Apc-Alexa Fluor...
...de Synthesis , 20 Amino Acid length max , MS-sp... customer for future usage conjugation of peptide ...2 days/each , Pre-immune bleed x1 /each , Im...leed (app. 5 ml) x1 /each , Production bleed (...
Rat TIMP-1 ELISA development Kit, DuoSet from R&D Systems
...ted Capture Antibody: 12 x 8-well strips, 3 plasti... 2X concentrate , Beta Amyloid 1-40 Standard: 1...d Standard Diluent: 3 mL , Primary Antibody: 150...HRP: 30 microL of concentrate , OPD Substrate: 2...
Biology Products: